Jun 16, 2025 Step by Step Guide to Prepare for ACRP-CP Exam BrainDumps
ACRP Certified Professional ACRP-CP Real Exam Questions and Answers FREE Updated on 2025
NEW QUESTION # 49
Access to study documentation for auditors and inspectors during an audit or inspection at a clinical trial site is the responsibility of the:
- A. PI
- B. CRC
- C. Sponsor
- D. CRA
Answer: A
Explanation:
The Principal Investigator (PI) is responsible for providing access to study documentation during an audit or inspection. This includes regulatory files, participant records, and study logs. The PI ensures that auditors and inspectors have appropriate access while maintaining the confidentiality of subject data.
GCP guidelines clearly assign the responsibility for maintaining and granting access to trial documentation to the PI at the study site.
"The PI is responsible for ensuring that study-related documents are available for review during audits or inspections." Objectives:
* Maintain transparency during inspections.
* Ensure compliance with documentation requirements.
NEW QUESTION # 50
The sponsor must report a serious unexpected AE to the regulatory authorities within a maximum of:
- A. 7 calendar days
- B. 15 calendar days
- C. 8 calendar days
- D. 30 calendar days
Answer: B
Explanation:
The sponsor is required to report serious unexpected adverse events (SAEs) to the regulatory authorities within 15 calendar days from the date of awareness. This reporting period is mandated to ensure that any new safety information that may affect the risk/benefit profile of the investigational product (IP) is promptly communicated, thereby protecting participant safety.
GCP guidelines specify that serious, unexpected, and related AEs must be reported to regulatory authorities within 15 days of being known to the sponsor.
"Serious unexpected adverse reactions that may affect the safety profile of the IP must be reported within 15 calendar days to the regulatory authorities." Objectives:
* Ensure timely reporting of safety information.
* Protect the safety of trial participants.
NEW QUESTION # 51
Preliminary evidence suggests a low-dose anti-cancer drug given for a short period of time may reduce the risk of developing cancer in patients who are at increased risk for developing cancer. The drug has potentially serious side effects. What is the MOST important question to consider before designing a clinical trial to test this hypothesis?
- A. How effective is the drug at treating patients that have been previously diagnosed with cancer?
- B. How does the risk of developing cancer compare to the anticipated side effects from the drug?
- C. How likely are patients at high risk of cancer going to develop cancer during the study?
- D. How willing are current patients to participate in a trial with potentially serious side effects?
Answer: B
Explanation:
Before initiating a clinical trial with a drug that has potentially serious side effects, it is essential to evaluate the risk-benefit ratio. The primary consideration is whether the potential benefits (reduced cancer risk) outweigh the risks (serious side effects). This assessment is fundamental to ethical clinical trial design.
The answer is verified as per GCP and ethical guidelines, which require a thorough assessment of risk versus benefit before conducting human trials.
"An assessment of potential benefits versus risks is a fundamental principle in the ethical design of clinical trials, especially when potential adverse effects are severe." Objectives:
* Ensure ethical considerations in trial design.
* Assess the potential harm versus benefit to participants.
NEW QUESTION # 52
The PI may assign responsibility for IP accountability to the pharmacist provided they are:
- A. An employee of the institution.
- B. Approved by the IRB/IEC.
- C. Under the supervision of the PI.
- D. Licensed to practice medicine.
Answer: C
Explanation:
The Principal Investigator (PI) can delegate the responsibility for investigational product (IP) accountability to a pharmacist as long as the pharmacist operates under the PI's supervision. This ensures that the pharmacist's actions remain compliant with the protocol and regulatory requirements.
According to GCP guidelines, the PI retains overall responsibility for IP management, even when tasks are delegated to other qualified staff members.
"The investigator may delegate IP management responsibilities to a pharmacist, provided the pharmacist works under the PI's direct supervision." Objectives:
* Maintain accountability for investigational products.
* Ensure proper delegation of IP responsibilities.
NEW QUESTION # 53
A protocol amendment is needed to collect additional data from a participant's medical record. When can the research team begin collecting the additional data?
- A. As soon as the protocol amendment is submitted to the IRB/IEC
- B. After the original planned data collection is completed
- C. After the protocol amendment is approved by the IRB/IEC
- D. When the need for the additional data is discovered
Answer: C
Explanation:
The research team must wait until the protocol amendment is reviewed and approved by the IRB/IEC before collecting any additional data. This ensures that any changes to the data collection process have undergone ethical review and comply with regulatory requirements. Collecting data without IRB/IEC approval would be a violation of Good Clinical Practice (GCP).
GCP guidelines clearly state that any changes to the protocol, including additional data collection, must be approved by the IRB/IEC before implementation.
"Any amendment that affects participant data collection must receive IRB/IEC approval before the change is implemented." Objectives:
* Maintain compliance with ethical standards.
* Protect participants' rights and data integrity.
NEW QUESTION # 54
A sponsor writes a protocol comparing an IP XYZ to a marketed drug ABC to determine if XYZ is more efficacious in the target population than ABC. Both drugs are prepared in identically masked IV bags and distributed according to the randomization scheme outlined in the protocol such that the study team is unaware of the treatment assignment.
Which of the following is an appropriate title for this study?
- A. A randomized, open-label, comparator study comparing the efficacy of XYZ to ABC in the target population
- B. A randomized, double-blind, double-dummy, superiority study comparing the efficacy of XYZ to ABC in the target population
- C. A randomized, single-blind, placebo-controlled study comparing the efficacy of XYZ to ABC in the target population
- D. A randomized, double-blind, superiority study comparing the efficacy of XYZ to ABC in the target population
Answer: D
Explanation:
Since both the investigator and the participant are unaware of the treatment assignment, the study is classified as double-blind. The study aims to establish the superiority of XYZ over ABC, making it a superiority study.
The use of masked IV bags confirms the double-blind design.
The answer is verified from GCP guidelines on blinding and superiority study designs.
"In double-blind studies, neither the participant nor the investigator knows the treatment assignment, which prevents bias." Objectives:
* Understanding blinding methods in clinical trials
* Ensuring unbiased efficacy comparisons
NEW QUESTION # 55
Who determines what criteria and procedures should be followed if a subject discontinues/withdraws their consent?
- A. Sponsor
- B. CRO
- C. PI
- D. Subject
Answer: A
Explanation:
The sponsor is responsible for defining the criteria and procedures for subject withdrawal or discontinuation of consent. This includes specifying how data already collected will be handled and whether any follow-up is required. The procedures must be clearly outlined in the study protocol and communicated to the research team.
This answer follows GCP guidelines, which state that the sponsor must ensure that procedures for subject withdrawal are clearly defined and documented.
"The sponsor is responsible for defining procedures to be followed if a subject discontinues participation or withdraws consent, including handling of data collected prior to withdrawal." Objectives:
* Ensure transparent procedures for participant withdrawal.
* Maintain data integrity while respecting participant autonomy.
NEW QUESTION # 56
An interim analysis is conducted during a clinical trial. To review the results, the sponsor assigns:
- A. Independent qualified individuals.
- B. Investigators participating in the trial.
- C. Executive board members.
- D. Regulatory authority expert advisors.
Answer: A
Explanation:
Interim analysis should be reviewed by independent qualified individuals, such as members of a Data Safety Monitoring Board (DSMB) or Independent Data Monitoring Committee (IDMC). This ensures that the analysis is unbiased and that decisions regarding continuation, modification, or termination of the trial are made objectively.
GCP guidelines emphasize that interim data should be reviewed by an independent committee to prevent bias and ensure participant safety.
"Interim analyses should be conducted by independent experts to maintain objectivity and safeguard trial integrity." Objectives:
* Maintain impartiality during interim analysis.
* Ensure unbiased decision-making regarding trial continuation.
NEW QUESTION # 57
Which document confirms the PI's agreement to permit auditing at the study site?
- A. IB
- B. ICF
- C. Protocol
- D. Delegation Log
Answer: B
Explanation:
The Informed Consent Form (ICF) typically includes a statement indicating that the participant's records may be reviewed by monitors, auditors, and regulatory authorities. This ensures transparency and compliance with regulatory requirements, allowing for audits and inspections when necessary.
This answer follows GCP guidelines which specify that the ICF should include consent for audits and inspections to protect subject confidentiality while ensuring data integrity.
"The ICF must include a statement allowing access to trial data for monitoring, auditing, and regulatory inspection purposes." Objectives:
* Ensure informed consent for data access.
* Facilitate compliance with auditing requirements.
NEW QUESTION # 58
The PI should ensure that source data is:
- A. On worksheets that are provided by the sponsor.
- B. Kept on site for a minimum of 2 years.
- C. Printed directly from the EMR.
- D. Accurately reflected in the eCRFs.
Answer: D
Explanation:
The PI is responsible for ensuring that the source data is accurately recorded in the electronic Case Report Forms (eCRFs). This accurate transposition of data is critical to maintaining data integrity and ensuring that the data collected at the site is consistent with the reported clinical outcomes.
GCP guidelines specify that source data should be accurate, legible, and directly reflected in the CRFs to maintain consistency and reliability.
"The PI must ensure that the source data are accurately and completely recorded in the eCRFs to maintain data integrity." Objectives:
* Ensure accurate data transposition from source to CRF.
* Maintain high standards of data quality and reliability.
NEW QUESTION # 59
The process of ensuring and documenting that an electronic data processing system conforms to the sponsor's established requirements for completeness, accuracy, reliability, and consistent intended performance is called:
- A. Quality Control
- B. Quality Assurance
- C. Validation
- D. Programming
Answer: C
Explanation:
Validation is the process of ensuring that an electronic data processing system meets the sponsor's specifications for completeness, accuracy, reliability, and consistent performance. It involves systematic testing and documentation to demonstrate that the system functions as intended, especially in the context of capturing, processing, and managing clinical trial data.
GCP guidelines specify that validation of electronic systems is crucial to maintain data integrity and compliance with regulatory standards.
"Validation ensures that electronic data systems function according to the sponsor's requirements, maintaining data accuracy and reliability." Objectives:
Maintain data integrity and reliability.
Demonstrate system compliance with regulatory requirements.
NEW QUESTION # 60
What would a sponsor use to implement and maintain quality in a study?
- A. Clinical trial agreement
- B. Standard operating procedures
- C. Statistical analysis plan
- D. Protocol signature pages
Answer: B
Explanation:
Standard Operating Procedures (SOPs) are essential for implementing and maintaining quality in a clinical study. SOPs outline the standardized methods for conducting study-related tasks, ensuring consistency, compliance, and quality across all trial sites. They are critical for training personnel, guiding the conduct of study activities, and maintaining protocol adherence.
GCP guidelines state that sponsors must develop and maintain SOPs to ensure the quality and consistency of clinical trial processes.
"The sponsor should establish SOPs to maintain the quality of clinical trials, covering all aspects of trial conduct, data handling, and safety management." Objectives:
* Ensure consistent and high-quality trial conduct.
* Standardize procedures across trial sites.
NEW QUESTION # 61
SAEs must be reported immediately by the site to the:
- A. DSMB/IDMC.
- B. Sponsor.
- C. Regulatory agency.
- D. IRB/IEC.
Answer: B
Explanation:
Serious Adverse Events (SAEs) must be reported immediately to the sponsor. The sponsor then assesses the severity, causality, and potential impact on the study and decides whether further reporting to regulatory authorities and IRB/IEC is required. Immediate reporting ensures that appropriate actions are taken to safeguard participant safety.
GCP guidelines specify that the site must notify the sponsor immediately about any SAE to ensure timely safety assessment and reporting.
"Sites must report all serious adverse events immediately to the sponsor, who will then determine the appropriate regulatory and ethical reporting requirements." Objectives:
* Ensure rapid reporting of serious adverse events.
* Maintain safety monitoring during the trial.
NEW QUESTION # 62
An investigator participating in a multicenter clinical trial has had 2 of the 4 subjects admitted to the emergency room for life-threatening infections. The investigator made the decision to stop treatment with IP and test for infections in the remaining subjects. What are the NEXT steps the investigator should take?
- A. Update the IB to add the risk of infection and submit to the sponsor for approval.
- B. Discontinue current subjects from the study and monitor subjects for any anticipated safety events.
- C. Add the risk of infection to the ICF and submit to the IRB/IEC for review.
- D. Notify the sponsor of the change in study plan and submit the deviation to the IRB/IEC for review.
Answer: D
Explanation:
The investigator must promptly notify the sponsor about the observed safety concerns and the decision to stop the IP administration. This constitutes a protocol deviation that must be reported tothe IRB/IEC for ethical oversight. It is essential to document the deviation accurately and seek guidance on whether to continue or modify the study procedures.
GCP guidelines require that significant deviations impacting participant safety be reported to both the sponsor and the IRB/IEC for appropriate review and action.
"Significant safety-related deviations must be reported promptly to the sponsor and IRB/IEC to ensure proper oversight and participant protection." Objectives:
Ensure prompt reporting of safety concerns.
Maintain compliance with ethical oversight requirements.
NEW QUESTION # 63
A potential subject is interested in a new clinical trial and would like to learn more about the risks and benefits of participation. Where can they find this information?
- A. IB
- B. ICF
- C. Protocol
- D. Package insert
Answer: B
Explanation:
The Informed Consent Form (ICF) contains comprehensive information about the potential risks and benefits of participation in a clinical trial. It is a legally required document that ensures that subjects make an informed decision before enrollment.
The answer is consistent with GCP guidelines which mandate that the ICF clearly outlines the risks and benefits of participation to protect participant rights.
"The ICF should include a clear explanation of potential risks and benefits to ensure informed decision- making by the participant." Objectives:
* Ensure informed decision-making by potential subjects.
* Provide transparent risk-benefit information.
NEW QUESTION # 64
......
Ultimate Guide to Prepare ACRP-CP Certification Exam for ACRP Certified Professional: https://www.ipassleader.com/ACRP/ACRP-CP-practice-exam-dumps.html
ACRP-CP Ultimate Study Guide: https://drive.google.com/open?id=1bpNQ3R3KwwGinTRHuGrEpC9J5vkSvQV4